麻豆果冻传媒影音

The Society of Hematologic Oncology (SOHO) will hold its 10th annual meeting this week in Houston.

As described by the president of SOHO, Moshe Talpaz, MD, of the University of Michigan Rogel Cancer Center, and the society's secretary, Hagop Kantarjian, MD, of the University of Texas MD Anderson Cancer Center, SOHO was established in 2012 as the only society specific to the field of hematologic malignancies.

This year's meeting will focus on new advances and practical clinical applications, with a special emphasis on novel biological therapeutic approaches, for acute lymphoblastic leukemia, acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia, Hodgkin lymphoma, T-cell lymphoma, mantle cell lymphoma, aggressive B-cell lymphoma, indolent B-cell lymphoma, myelodysplastic syndromes (MDS), myeloproliferative neoplasms, and multiple myeloma.

Plenary sessions will include:

• A total approach to MDS presented by Guillermo Garcia-Manero, MD, of the University of Texas MD Anderson Cancer Center
• Meeting the challenge of resistance to targeted therapies in CLL presented by Thomas Kipps, MD, PhD, of the University of California San Diego
• Future directions of CAR T-cell therapy in lymphoma presented by Sattva S. Neelapu, MD, of the University of Texas MD Anderson Cancer Center

There will also be a number of "state-of-the-art" sessions for each topic, including:

• Non-intensive treatment of elderly and/or unfit patients with AML by Tapan M. Kadia, MD, of the University of Texas MD Anderson Cancer Center
• Minimal residual disease (MRD) assessments in multiple myeloma by Rafael Fonseca, MD, of the Mayo Clinic in Phoenix
• Current covalent BTK inhibitors in CLL by John C. Byrd, MD, of the Ohio State University Comprehensive Cancer Center in Columbus
• Sequencing novel agents in front-line and second-line treatment of Hodgkin lymphoma by Alison Moskowitz, MD, of Memorial Sloan Kettering Cancer Center in New York City
• A debate on T-cell engagers versus CAR T-cell therapy for relapsed/refractory multiple myeloma by Saad Z. Usmani, MD, MBA, of Memorial Sloan Kettering Cancer Center, and Thomas G. Martin, MD, of the University of California San Francisco

SOHO has accepted hundreds of abstracts as poster presentations, including 12 that will be presented as oral abstracts during the course of the meeting.

The meeting runs from Wednesday, September 28, to Saturday, October 1.

Comment